Clear All
793 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
Repotrectinib Augtyro 40mg, 160mg Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Yes 2023 In Use
NA Trifluridine and Tipiracil Lonsurf 15/6.14 mg Chemotherapy Antimetabolite Pyrimidine Analog Yes 2015 In Use
NA Palbociclib Ibrance 125 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2015 In Use
NA Ribociclib Kisqali 200 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Cyclosporine Gengraf 25mg, 50mg, 100mg Ancillary Therapy Immunomodulator Calcineurin Inhibitor Yes 2010 In Use
NA cobimetinib Cotellic 20 mg Chemotherapy MAPK/MEK Inhibitor BRAF Yes 2015 In Use
NA Flutamide Euflex, Eulexin 125 mg Hormonal Therapy Androgen Receptor Inhibitor Yes 1989 In Use
Olutasidenib Rezlidhia 150mg Chemotherapy Enzyme Inhibitor IDH1 Yes 2022 In Use
NA Uridine Triacetate Xuriden 2 g Ancillary Therapy Chemoprotective Antidote Yes 2015 In Use
NA Glasdegib Daurismo 25mg, 100mg Chemotherapy Hedgehog Pathway Inhibitor SMO Yes 2018 In Use
NA Uracil Mustard Uramustine unspecified Chemotherapy Alkylating Agent Nitrogen Mustard No 1962 1999 No Longer Used
Revumenib Revuforj 25mg, 110mg, 160mg Chemotherapy Enzyme Inhibitor KMT2A Yes 2024 In Use
NA Diethylstilbestrol DES, Stilbestrol unspecified Hormonal Therapy Estrogen No 1905 2000 In Use
NA Relugolix Orgovyx 120mg Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist Yes 2020 In Use
Olutasidenib Rezlidhia 150mg Chemotherapy Enzyme Inhibitor IDH1 Yes 2022 In Use
NA Tivozanib Fotivda 0.89mg, 1.34mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2021 In Use
Not yet assigned Inotuzumab Ozogamicin Besponsa 0.9 mg Immunotherapy Drug Antibody Conjugate CD22 No 2017 In Use
NA Ibrutinib Imbruvica 140 mg Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Yes 2014 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.